NASDAQ:BJDX Bluejay Diagnostics Q4 2024 Earnings Results & Report $0.82 +0.01 (+0.68%) Closing price 04:00 PM EasternExtended Trading$0.79 -0.03 (-3.26%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bluejay Diagnostics missed analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$449.48 versus the -$144.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 31, 2025TimeBefore Market Opens Bluejay Diagnostics EPS ResultsActual EPS-$449.48Consensus EPS -$144.00Beat/MissMissed by -$305.48One Year Ago EPSN/ABluejay Diagnostics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBluejay Diagnostics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Bluejay Diagnostics Q4 2024 Earnings FAQ Did Bluejay Diagnostics beat earnings estimates for Q4 2024? Bluejay Diagnostics (NASDAQ:BJDX) reported earnings of -$449.48 per share for Q4 2024, missing the consensus estimate of -$144.00. The report was announced on Monday, March 31, 2025. When is Bluejay Diagnostics' next earnings date? Bluejay Diagnostics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bluejay Diagnostics on the company's earnings history page. Bluejay Diagnostics Earnings HeadlinesBluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest UpdateOctober 1, 2026 | americanbankingnews.com5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & AtaraSeptember 8, 2026 | rttnews.comA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn.October 8 at 1:00 AM | TradeWins (Ad)Bluejay Diagnostics federal healthcare partnership builds commercial pathway ahead of FDA clearanceSeptember 8, 2026 | msn.comBluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare MarketSeptember 8, 2026 | rttnews.comBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsSeptember 8, 2026 | markets.businessinsider.comSee More Bluejay Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email. Email Address About Bluejay DiagnosticsBluejay Diagnostics (NASDAQ:BJDX) is a medical technology company focused on developing rapid, decentralized diagnostic solutions for use at the point of care. The company’s products are designed to help healthcare professionals obtain timely information from blood samples, supporting clinical decision-making in acute-care settings. Bluejay’s primary technology is the Symphony System, a compact analyzer and disposable testing platform intended to measure clinically relevant biomarkers from whole blood. The system is designed to provide results near the patient rather than requiring samples to be sent to a centralized laboratory. The company has focused its development efforts on applications such as sepsis and other conditions in which rapid assessment may assist with patient management. Bluejay Diagnostics is based in the United States and has directed its activities primarily toward the U.S. healthcare market. The company continues to develop and advance its Symphony platform and related diagnostic applications for hospitals, emergency departments, and other acute-care environments.View Bluejay Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
